Related Experiment Video
Updated: Jul 29, 2026
07:25
Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology
Published on: March 27, 2018
Diminished synaptosomal dopamine (DA) release and DA autoreceptor supersensitivity in schizophrenia
L Hetey1, R Schwitzkowsky, T Ott
1Institute of Pharmacology and Toxicology of Charité, Humboldt University Berlin, German Democratic Republic.
Journal of Neural Transmission. General Section
|January 1, 1991
Summary
Schizophrenia is linked to reduced dopamine release in specific brain areas. This study also found enhanced dopamine autoreceptor function in these regions, independent of medication effects.
Area of Science:
- Neuroscience
- Psychiatry
- Molecular Biology
Background:
- Dopamine signaling is implicated in schizophrenia pathophysiology.
- Dysregulation of dopamine release and autoreceptor function may contribute to the disorder.
Purpose of the Study:
- To investigate dopamine release and autoreceptor function in post-mortem brain regions of individuals with schizophrenia compared to controls.
- To determine if observed alterations are related to medication.
Main Methods:
- Post-mortem brain specimens from schizophrenic patients and matched controls were cryopreserved.
- Synaptosomes were used to measure K(+)-stimulated [3H]dopamine release.
- Data were corrected for post-mortem delay; dopamine autoreceptor function was assessed.
Main Results:
- Significantly diminished K(+)-stimulated [3H]dopamine release was observed in the nucleus accumbens and caudate nucleus of schizophrenic brains.
- Functional supersensitivity of modulatory dopamine autoreceptors was demonstrated in these regions.
- Similar alterations were found in neuroleptic-free patients, suggesting they are not primarily medication-induced.
Conclusions:
- Schizophrenia is associated with reduced dopamine release and enhanced dopamine autoreceptor sensitivity in key brain regions.
- These findings suggest intrinsic dopaminergic system alterations in schizophrenia.
- The observed changes are likely independent of antipsychotic medication.
Related Concept Videos
01:20Desensitization and Tachyphylaxis
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Several...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:21Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
01:29Biological Causes of Schizophrenia
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...